Lotte Biologics: "Songdo Plant to Generate Up to 700 Billion Won Annually...1 Trillion Won Target by 2030"
Revenue to Begin Next Year... Commercial Production to Ramp Up in 2028
Linking Korea-U.S. Production Sites to Expand Global Orders
Shin Dong-bin: "I Hope It Will Mark a Turning Point in Boosting K-Bio's Competitiveness"
Lotte Biologics is aiming to achieve 1 trillion won in revenue by 2030, using its biopharmaceutical production plant in Songdo, Incheon, as a springboard. The company plans to generate up to 700 billion won annually from its Songdo Plant 1 and step up its push into the global contract development and manufacturing organization (CDMO) market by establishing an integrated production system with its Syracuse plant in the United States. With cumulative orders nearing $1.9 billion just four years after its launch, the company is expected to begin generating revenue from its Songdo plant next year.
On November 18, Lotte Biologics held a press conference to mark the completion of Plant 1 at the Songdo Bio Campus in Yeonsu-gu, Incheon, and announced its business strategy. "The completion of the Songdo Bio Campus is an important starting point for taking on new challenges in the global CDMO market, backed by the large-scale production infrastructure we have been preparing," said James Park, CEO of Lotte Biologics. "We will establish ourselves as a trusted CDMO company through top-tier quality and operational competitiveness."
Company officials take part in a ceremony at the completion ceremony for Lotte Biologics’ Plant 1 at the Songdo Bio Campus in Yeonsu-gu, Incheon, on the 18th. From left: Tamatsuka Genichi, CEO of Lotte Holdings; Jung Il-young, National Assembly member; Shin Yoo-yeol, CEO of Lotte Biologics; Park Chan-dae, mayor of Incheon; Shin Dong-bin, chairman of Lotte Group; Song Young-gil, National Assembly member; Noh Joon-hyung, CEO of Lotte Corp.; Kim Jong-cheol, head of the Incheon Free Economic Zone Authority; and Park James, CEO of Lotte Biologics. Lotte Biologics
View original imageCumulative Orders Near $1.9 Billion...Commercial Production to Ramp Up in 2028
Lotte Biologics entered the CDMO business in 2022 by acquiring Bristol Myers Squibb's (BMS) Syracuse plant in the United States. It has since pursued a strategy of building a large-scale production facility in Songdo alongside that acquisition. The company secured business experience and a customer base by acquiring an existing production facility while also moving ahead with the construction of a new plant in Korea.
According to Lotte Biologics, cumulative orders since its launch have reached nearly $1.9 billion. The company also announced on November 17, one day before the completion ceremony, that it had signed its first large-scale commercial production contract for the Songdo plant with a global pharmaceutical company. It did not disclose the customer or the size of the order, but the deal is seen as laying the groundwork for future revenue by securing a customer ahead of commercial production.
Jeon Jiwon, head of strategic planning at Lotte Biologics, cited a strategy of "selective focus" as the reason for the growth in orders. "As a late entrant, rather than trying to be chosen by every customer, we first chose customers who would place greater value on our strengths," Jeon said. The company focused its sales efforts on customers that need the strengths Lotte Biologics offers, including local production in the United States, supply chain diversification, and antibody-drug conjugate (ADC) manufacturing.
Lotte Group Chairman Shin Dongbin (third from left) and Lotte Biologics CEO Shin Yuyeol attended the completion ceremony for Plant 1 at the Songdo Bio Campus in Yeonsu-gu, Incheon, on the 18th. Lotte Biologics
View original imageRevenue is also expected to grow more quickly once the Songdo plant is fully operational. Lotte Biologics estimates that Plant 1 could generate up to 700 billion won annually at full capacity, while its Syracuse plant in the United States could generate up to 300 billion won. Together, the two production sites provide the company with a production base capable of supporting 1 trillion won in annual revenue.
However, it is expected to take time to achieve profitability from commercial production. "Revenue will begin to come in from 2027, as it is also generated during technology transfers, trial production, and the manufacturing of products for regulatory approval," said Kang Hyunsim, head of finance at Lotte Biologics. "Taking into account the time required for regulatory approval, full-scale commercial production will begin in 2028."
Production Process Designed to Use Gravity...120,000-Liter Production Facility Secured
On the fourth floor of Songdo Plant 1, which reporters toured that day, was a quality control (QC) laboratory for analyzing media and buffer solutions used in production. One floor below, on the third floor, were eight 15,000-liter bioreactors, the plant's core equipment. Songdo Plant 1 has a total production capacity of 120,000 liters.
The plant's design also incorporates technology to improve production efficiency. The five-story facility was designed to use gravity to move raw materials and culture fluids from upper floors to lower floors. "Media and buffer solutions are prepared on the fifth floor, cells are cultured on the third floor, the harvesting process takes place on the second floor, and purification is carried out on the first floor," said Jung Woochung, head of EPC. "Minimizing mechanical transfers reduces the risk of cell damage and also saves energy."
A view of Plant 1 at Lotte Biologics' Songdo Bio Campus in Yeonsu-gu, Incheon. Lotte Biologics
In addition to large-scale bioreactors, the plant is equipped with 3,000-liter units to enable production of a range of products, including high-titer antibody drugs. It has also raised the level of automation in logistics and quality control, including by introducing autonomous mobile robots to transport samples within the facility. The company achieved "GMP Ready" status, the preparatory stage for good manufacturing practice (GMP), six months ahead of its original target.
Leveraging Korea-U.S. "Dual-Site" Strategy to Target Global Supply Chains
Lotte Biologics plans to pursue a "Dual Site" strategy that combines Songdo's large-scale production capacity with the commercial production experience of its Syracuse plant in the United States. Rather than simply operating the two plants separately, experts from the company's production facilities in both countries will work together from the initial customer consultation stage to select the production site best suited to each product's characteristics and support technology transfers.
The company also plans to capitalize on the tariff advantages of producing locally in the United States. "It is important to integrate the proven quality and production capabilities in the United States with Korea's advanced infrastructure and speed," Jeon said. "We will offer the combined strengths of both production sites to match each customer's development strategy and production scale."
Lotte Biologics also plans to expand production capacity by building Songdo Plants 2 and 3 and to enter the capital markets. However, the timing of additional plant construction and an initial public offering (IPO) will be decided flexibly, taking into account future orders, customer pipelines, and market conditions.
At the completion ceremony that morning, Lotte Group Chairman Shin Dong-bin said, "The biopharmaceutical business is a future growth engine for Lotte Group and a next-generation industry that will lead the next generation of Korea. I hope Songdo Plant 1 in Incheon will become an important turning point that not only drives Lotte Group's growth but also raises the competitiveness of Korea's biopharmaceutical industry to a new level."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.